Your AI-Trained Oncology Knowledge Connection!
Krina K. Patel, MD, MSc, expands on the importance of evaluating outcomes for treatment with ide-cel in patients with relapsed/refractory multiple myeloma with different high-risk characteristics and key findings from the high-risk subgroup analysis of the KarMMa-3 trial.
The use of prostate stem cell antigen–targeted CAR T-cell therapy was well tolerated and produced evidence of anticancer effects in patients with metastatic castration-resistant prostate cancer.
The FDA has granted orphan drug designation to padeliporfin vascular targeted photodynamic therapy for use as a potential therapeutic option in patients with locally advanced pancreatic cancer.
The combination of botensilimab and balstilimab elicited durable responses and provided overall survival benefits in patients with microsatellite stable metastatic colorectal cancer that is resistant to chemotherapy and/or immunotherapy.
Julien Taieb, MD, discusses the importance of combining fluoropyrimidines with bevacizumab, key findings from the SUNLIGHT trial and the post-hoc analysis, and how these results may shake up the colorectal cancer treatment paradigm.
Treatment with the irreversible BTK inhibitor abivertinib led to responses and disease control in patients with relapsed/refractory marginal zone lymphoma.
Jersey Shore University Medical Center is among the first hospitals in New Jersey to provide the HAI pump, which is offered at few hospitals in the country, enabling the N.J. community to stay close to home for care.
The FDA has approved a new drug application for 200-mg/mL vials of cyclophosphamide injection for use in combination therapy in the treatment of patients with various types of cancers, including malignant lymphoma, multiple myeloma, and various types of leukemia.
Datopotamab deruxtecan provided a statistically significant improvement in progression-free survival compared with standard-of-care docetaxel in patients with locally advanced or metastatic non–small cell lung cancer who received at least 1 prior line of therapy.
Adagrasib has demonstrated intracranial activity among patients with KRAS G12C–mutated non–small cell lung cancer with untreated central nervous system metastases.
A treatment regimen consisting of pepinemab plus trastuzumab and a dendritic cell vaccine, followed by autologous CD4-positive T cells, is under investigation in a phase 1 trial in patients with metastatic HER2-positive breast cancer.
The combination of disitamab vedotin with toripalimab generated responses and displayed a manageable safety profile in patients with locally advanced or metastatic urothelial carcinoma, irrespective of HER2 expression.
The combination of the oncolytic reovirus pelareorep and paclitaxel generated responses in patients with metastatic hormone receptor–positive/HER2-negative breast cancer.
The addition of first-line maintenance avelumab to best supportive care has sustained tolerability in patients with advanced urothelial carcinoma.
huCART19-IL8 had acceptable safety and induced durable responses in patients with lymphoma who were refractory or relapsed following second-generation CD19-targeted CAR T-cell therapies, according to data from a first-in-human phase 1 trial.
ONC-392/BNT316 demonstrated early signs of antitumor activity and manageable safety in patients with metastatic, PD-(L)1–resistant non–small cell lung cancer.
Lower rates of diarrhea and overall bowel dysfunction were reported with the use of neoadjuvant fluorouracil and oxaliplatin vs neoadjuvant pelvic chemoradiation with fluorouracil (5FCURT) in patients with locally advanced rectal cancer. However, lower rates of other toxicities were reported in patients treated with 5FCURT.
The FDA has granted breakthrough therapy designation to zenocutuzumab for use as a potential therapeutic option in patients with advanced unresectable or metastatic NRG1 fusion–positive pancreatic cancer after disease progression on previous systemic therapy or who have no satisfactory alternative options available.
Harry Gill, MD, discusses the rationale for exploring ropeginterferon alfa-2b as a potential treatment option for patients early myelofibrosis and expands on the efficacy and safety data observed in the phase 2 study.
Bradley J. Monk, MD, FACS, FACOG, discusses the rationale for investigating avutometinib plus defactinib in patients with low-grade serous ovarian cancer, key findings from RAMP 201, and how this research may influence the ovarian cancer treatment paradigm going forward.
The US indication for pralsetinib in the treatment of adult and pediatric patients aged 12 years and older with advanced or metastatic RET-mutant medullary thyroid cancer who require systemic therapy has been voluntarily withdrawn by Genentech.
A new study from Fox Chase Cancer Center that was featured on the cover of the Journal of Urology, published by Wolters Kluwer sheds more light on cystic renal masses.
Durvalumab plus a single priming dose of tremelimumab led to continued clinically meaningful overall survival benefit at 4 years compared with sorafenib in patients with previously untreated, unresectable hepatocellular carcinoma not eligible for localized therapy.
Pembrolizumab led to sustained improvements in recurrence-free survival and distant metastasis–free survival vs placebo as adjuvant therapy in patients with resected stage IIB or IIC melanoma
The European Commission has granted an orphan drug designation to Temferon for the treatment of patients with glioma, joining glioblastoma multiforme in its designation.
Treatment with intra-arterial gemcitabine led to an improvement in overall survival compared with continued treatment with intravenous gemcitabine plus nab-paclitaxel in patients with locally advanced pancreatic cancer following sequential treatment with IV gemcitabine, nab-paclitaxel, and radiotherapy.
The treatment landscape for PNH is rapidly evolving, and clinicians have more effective and convenient treatment options for patients that have helped control the disease and improve survival. T
The European Commission has approved nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of patients with resectable non–small cell lung cancer at high risk of recurrence with tumor cell PD-L1 expression of at least 1%.
The addition of the CXCL12 inhibitor NOX-A12 to standard frontline therapy with radiation and bevacizumab led to an overall survival rate of 83% at a median follow-up of 15 months in patients with glioblastoma.
Although the highly potent, selective, allosteric, oral, small molecule BRG1/BRM inhibitor FHD-286 elicited signs of clinical activity and safety as monotherapy in patients with metastatic uveal melanoma in the dose-escalation portion of a phase 1 trial, further development in this indication will not be pursued.
